Dyes for Analysis of Soluble Protein Aggregates or Misfolded Protein Oligomers
20210094922 · 2021-04-01
Inventors
- Xin Zhang (State College, PA, US)
- Yu Liu (State College, PA, US)
- Charles Wolstenholme (Fairfield, CT, US)
Cpc classification
G01N21/6428
PHYSICS
C07F9/6506
CHEMISTRY; METALLURGY
C07D455/04
CHEMISTRY; METALLURGY
C07D403/06
CHEMISTRY; METALLURGY
C07D405/06
CHEMISTRY; METALLURGY
A61K49/0021
HUMAN NECESSITIES
C07F9/650952
CHEMISTRY; METALLURGY
C07D233/96
CHEMISTRY; METALLURGY
C09B23/04
CHEMISTRY; METALLURGY
C07D417/06
CHEMISTRY; METALLURGY
C09B23/145
CHEMISTRY; METALLURGY
C09B23/0075
CHEMISTRY; METALLURGY
International classification
C07D403/06
CHEMISTRY; METALLURGY
C07F9/6506
CHEMISTRY; METALLURGY
Abstract
Dye and compositions to monitor the multistep protein aggregation process in both test tubes and live cells are provided. These dyes can detect misfolded protein oligomers and distinguish insoluble protein aggregates from misfolded oligomers. Applications of these dyes include measuring kinetics of protein aggregation, monitoring aggregation of specific proteins in intact live cells, monitoring aggregation of cellular proteome in intact live cells, and tracking the time course of protein aggregation in cells under stress conditions.
Claims
1. A compound of Formula I: ##STR00266## wherein; R.sub.1, R.sub.2, and R.sub.5 are independently selected from the moieties of Group 1, and R.sub.4 is —H; R.sub.1, R.sub.2, and R.sub.4 are independently selected from the moieties of Group 1, and R.sub.5 is —H; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —H, and R.sub.5 is —H; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —H and R.sub.5 is —CH.sub.3; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —CH.sub.3 and R.sub.5 is —H; or R.sub.1, R.sub.2, R.sub.4, and R.sub.5 are independently selected from the moieties of Group 1; and wherein the moieties of Group 1 are selected from the group consisting of ##STR00267## ##STR00268## ##STR00269## ##STR00270## wherein substituents may be at para-, meta-, or ortho- positions on the aromatic ring, even if shown in only a single position above; and wherein R.sub.3 is a directing moiety that binds and bioconjugates at least one biological target, wherein R.sub.3 is selected from the group consisting of: ##STR00271## ##STR00272## Wherein R.sub.6 is selected from the group consisting of ##STR00273## and wherein n is 0, 1, 2, 3, 4 or 5.
2. A compound of Formula II: ##STR00274## wherein R.sub.1 and R.sub.7 are independently selected from a moiety of Group 1; or R.sub.1 is a moiety of Group 1, R.sub.7 is a moiety of Group 2, and R.sub.8 and R.sub.9 are independently selected from —H, —CH.sub.3, and a moiety of Group 1: wherein a moiety of Group 1 is selected from the ##STR00275## ##STR00276## ##STR00277## ##STR00278## and wherein a moiety of Group 2 is selected from the group consisting of ##STR00279## ##STR00280## wherein substituents may be at para-, meta-, or ortho- positions on the aromatic ring of Group 1 and Group 2, even if shown in only a single position above; and wherein R3 is a directing moiety to bind and bioconjugate to biological targets, selected from the group consisting of: ##STR00281## ##STR00282## wherein, R.sub.6 is selected from the group consisting of ##STR00283## and wherein n is 0, 1, 2, 3, 4 or 5.
3. (canceled)
4. A method for detecting at least one of aggregated protein, misfolded protein, and amyloid fiber in a protein of interest, comprising: performing a first measurement of fluorescence intensity of a protein of interest; adding to the protein of interest a fluorescent protein chromophore; and performing a second measurement of fluorescence intensity of the protein of interest; wherein increased fluorescence is indicative of at least one of aggregation, misfolding, and amyloid fiber in the protein of interest.
5. (canceled)
6. The method of claim 4, wherein the method is conducted in a cell in vivo.
7. The method of claim 4, wherein the method is conducted in vitro.
8. The method of claim 4, further comprising purifying the protein of interest prior to the first measurement.
9. The method of claim 4, wherein the fluorescent protein chromophore comprises a thioflavm-T guiding group or a tert-butyloxycarbonyl guiding group.
10. The method for detecting at least one of aggregated protein, misfolded protein, and amyloid fiber in a protein of interest of claim 4, said method comprising: performing a first measurement of fluorescence intensity of a standard protein; and comparing the fluorescence intensity of the standard protein with the fluorescence intensity of the protein of interest, wherein increased fluorescence of the protein of interest relative to the fluorescence intensity of the standard protein is indicative of at least one of aggregation, misfolding, and amyloid fiber in the protein of interest.
11. A kit for detecting at least one of aggregated protein, misfolded protein, and amyloid fiber, comprising: one or more fluorescent protein chromophores of claim 1 of a known concentration in a stock solution, one or more standard protein samples that form aggregated protein, misfolded protein, and amyloid fiber and optionally, instructions for use in detecting at least one of one of the aggregated protein, misfolded protein, and amyloid fiber.
12. The kit of claim 11 wherein the stock solution is dimethyl sulfoxide or ethanol.
13. A kit for detecting at least one of aggregated protein, misfolded protein, and amyloid fiber, comprising: one or more fluorescent protein chromophores of claim 2 of a known concentration in a stock solution, one or more standard protein samples that form aggregated protein, misfolded protein, and amyloid fiber and optionally, instructions for use in detecting at least one of one of the aggregated protein, misfolded protein, and amyloid fiber.
14. The method of claim 4, wherein the fluorescent protein chromophore is a compound of Formula I: ##STR00284## wherein; R.sub.1, R.sub.2, and R.sub.5 are independently selected from the moieties of Group 1, and R.sub.4 is —H; R.sub.1, R.sub.2, and R.sub.4 are independently selected from the moieties of Group 1, and R.sub.5 is —H; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —H, and R.sub.5 is —H; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —H and R.sub.5 is —CH.sub.3; R.sub.1 and R.sub.2 are independently selected from the moieties of Group 1, R.sub.4 is —CH.sub.3 and R.sub.5 is —H; or R.sub.1, R.sub.2, R.sub.4, and R.sub.5 are independently selected from the moieties of Group 1; and wherein the moieties of Group 1 are selected from the group consisting of ##STR00285## ##STR00286## ##STR00287## ##STR00288## wherein substituents may be at para-, meta-, or ortho- positions on the aromatic ring, even if shown in only a single position above; and wherein R.sub.3 is a directing moiety that binds and bioconjugates at least one biological target, wherein R.sub.3 is selected from the group consisting of: ##STR00289## ##STR00290## Wherein R.sub.6 is selected from the group consisting of ##STR00291## and wherein n is 0, 1, 2, 3, 4 or 5.
15. The method of claim 4, wherein the fluorescent protein chromophore is a compound of Formula II: ##STR00292## wherein R.sub.1 and R.sub.7 are independently selected from a moiety of Group 1; or R.sub.1 is a moiety of Group 1, R.sub.7 is a moiety of Group 2, and R.sub.8 and R.sub.9 are independently selected from —H, —CH.sub.3, and a moiety of Group 1; wherein a moiety of Group 1 is selected from the group consisting of: ##STR00293## ##STR00294## ##STR00295## ##STR00296## and wherein a moiety of Group 2 is selected from the group consisting of ##STR00297## ##STR00298## wherein substituents may be at para-, meta-, or ortho- positions on the aromatic ring of Group 1 and Group 2, even if shown in only a single position above; and wherein R3 is a directing moiety to bind and bioconjugate to biological targets, selected from the group consisting of: ##STR00299## ##STR00300## wherein, R.sub.6 is selected from the group consisting of ##STR00301## and wherein n is 0, 1, 2, 3, 4 or 5.
16. The method of claim 4, wherein the fluorescent protein chromophore is a compound of Table 1.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0040] The above and other objects, aspects, features, advantages and possible applications of the present innovation will be more apparent from the following more particular description thereof, presented in conjunction with the following drawings. Like reference numbers used in the drawings may identify like components.
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0066] While the terms used herein are believed to be well understood by one of ordinary skill in the art, definitions are set forth herein to facilitate explanation of the subject matter disclosed herein.
[0067] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter disclosed herein belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently disclosed subject matter, representative methods, devices, and materials are described herein.
[0068] The terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. The use of the word “a” or “an” when used in conjunction with the tenn “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
[0069] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
[0070] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0071] The methods and devices of the present disclosure, including components thereof, can comprise, consist of, or consist essentially of the essential elements and limitations of the embodiments described herein, as well as any additional or optional components or limitations described herein or otherwise useful.
[0072] Unless otherwise indicated, all numbers expressing physical dimensions, quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter.
[0073] As used herein, ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0074] The following description is of exemplary embodiments that are presently contemplated for carrying out the present invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of describing the general principles and features of the present invention. The scope of the present invention is not limited by this description.
[0075] As noted above, embodiments apply an FP chromophore to visualize protein misfolding and aggregation, using turn-on fluorescence, both in test tube and in live cells.
[0076] The present invention provides dyes, reagents and methods useful for detection of misfolded protein oligomers and insoluble protein aggregates in vitro and in vivo. In some embodiments, the invention provides a family of probes containing an imidazolinone core structure.
[0077] The probes of the invention are useful for generating fluorescence signals that depend upon the presence of an aggregated form of a protein, while conveying minimal levels of signals when only the native form of the protein is present.
[0078] Many of these probes exhibit large variation in their excitation and emission wavelength thereby allowing for potential multicolor detection of protein aggregation and sequential imaging.
[0079] Specific embodiments of FP chromophores are reported herein. Some of these FP chromophores are included in Table 1, below. In each cell of the table, a compound and its assigned compound number are presented:
TABLE-US-00001 TABLE 1 Compound Number Compound 1
[0080] In further embodiments as reported herein, protein aggregation and protein misfolding are detected by the disclosed compounds in test tubes. This detection can be conducted with or without covalent conjugation to proteins of interest. Normally, purified proteins are used in this detection. These proteins are subjected to in vitro conditions to induce protein misfolding and aggregation. Disclosed compounds can be added before, during, or after protein misfolding and aggregation. Fluorescence intensity can be recorded by fluorescence spectrophotometers or fluorescence microplate readers.
Compounds 1-5:
[0081] ##STR00258##
Testing Examples
[0082] Compound 1, which contains HBI, requires both deprotonation to phenolate and restriction of bond rotations to emit fluorescence (
[0083] Both 1 and 2 exhibit elevated fluorescence in solvents containing increasing concentrations of glycerol (spectra shown in
[0084] Further embodiments may extend n conjugation to both increase QY and restrict bond rotation (
[0085] Compound 3 exhibited higher QY and brightness than 1 and 2 in glycerol (Φ=0.22, comparable to D of the Kaede protein as 0.33; brightness shown in
[0086] Crystals of 3 exhibited fluorescence. While not wishing to be bound by theory, this suggests its aggregation induced emission (AIE) feature (
[0087] In the fluorescent crystal, 3 adopted a near planar structure (
[0088] Compound 3a and Compound 3b were also prepared, as shown above.
[0089] Compound 3a without electron-donating capacity at position A diminished quantum yield by ˜50%; whereas 3b without electron-donating capacity at position B does not affect quantum yield (Table 2). The absorptivity of both 3a and 3b was reduced (Table 2 and
TABLE-US-00002 TABLE 2 The photophysical parameters of fluorophores in the present invention. Com- λ.sub.ex λ.sub.em λ.sub.abs pound (nm) (nm) Φ (nm).sup.c ϵ(M.sup.−1cm.sup.−1).sup.c B(M.sup.−1cm.sup.−1).sup.d 1 370 429 0.001 376 20,592 20.6 2 450 521 0.027 452 23,718 640 3 530 629 0.221 530 39,049 8,786 3a 485 621 0.1 500 13,863 1,386 3b 530 630 0.232 533 9,004 2,089 4 530 628 0.230 534 36,241 8,734 aMaximum absorbance and extinction coefficient measured in glycerol. bBrightness (B) was calculated using B = Φϵ.
TABLE-US-00003 TABLE 3 The geometry of 3 extracted from crystal structure. The total energy at this geometry is −1531.67109379 Hartree. Atom X (Å) Y (Å) Z (Å) C 8.589111 −1.881432 1.224387 H 9.139859 −1.768830 0.445329 H 8.998082 −2.518740 1.813209 H 8.497810 −1.039027 1.676078 H 7.677154 −4.210787 1.409144 C 1.255841 2.555928 −1.372002 C 2.079860 1.358102 −1.047783 C 0.014408 0.720154 −0.976268 C 3.430059 1.410384 −0.977822 H 3.804300 2.224322 −1.228115 C 4.388472 0.388601 −0.571549 C 5.727878 0.741428 −0.476613 H 5.985943 1.603805 −0.707828 C 6.346334 −1.447938 0.341371 C 4.994563 −1.813307 0.214286 H 4.734045 −2.680516 0.424980 C 4.042570 −0.906792 −0.220101 H 3.153915 −1.172817 −0.278479 C 6.889460 −3.694201 1.224295 H 6.345074 −3.645782 2.012474 H 6.392083 −4.110123 0.517262 C −1.221120 −0.053142 −0.842227 H −2.028992 0.350472 −1.064420 C −1.230528 −1.321341 −0.411810 H −0.405583 −1.688712 −0.190991 C −2.393740 −2.195524 −0.248500 C −2.222585 −3.502827 0.192167 H −1.365663 −3.791036 0.412277 C −3.271420 −4.390282 0.317704 H −3.108393 −5.258111 0.608236 C −4.572196 −3.996638 0.008796 C −4.759688 −2.683641 −0.436285 H −5.616644 −2.396456 −0.654614 C −3.698918 −1.799250 −0.557339 H −3.857202 −0.929174 −0.848739 H −4.939809 −6.694154 −0.329524 C −1.183415 2.949098 −1.368345 H −1.934115 2.471932 −1.754659 H −0.988762 3.709282 −1.938351 C −1.562630 3.441717 0.009391 C −3.264926 4.838528 1.141641 C −2.270442 5.770712 1.793963 H −1.500405 5.271937 2.076998 H −2.677748 6.188832 2.556554 H −2.003097 6.444013 1.164576 C −3.736996 3.730646 2.074251 H −4.412066 3.210115 1.635228 H −4.099555 4.118614 2.875078 H −2.995042 3.164813 2.301043 C −4.455907 5.578691 0.551176 H −4.145729 6.238137 −0.073121 H −4.944598 6.008265 1.255781 H −5.027917 4.953304 0.100110 N 1.227433 0.271319 −0.822233 N −0.043023 2.084575 −1.330079 N 7.273613 −2.362966 0.822083 N −5.636442 −4.884588 0.135566 O 1.575820 3.732509 −1.579503 O −2.646351 4.215190 −0.068768 O −0.970195 3.171377 1.011101 C −6.986251 −4.455920 −0.216546 H −7.206796 −3.659886 0.273176 H −7.609525 −5.149602 0.002538 H −7.028281 −4.273958 −1.158477 C −5.403601 −6.297338 0.409664 H −4.873618 −6.386220 1.205418 H −6.246057 −6.740703 0.535678 C 6.689652 −0.155705 −0.046086 H 7.579008 0.113535 −0.016736
[0090] Synthesis of Example Compounds
##STR00259##
[0091] Scheme 1. Synthesis of GFP Mimic Precursors.
[0092] Cyclization reaction to form GFP core. Condition (a) glycine tert-butyl ester hydrochloride (1.1 eq) was combine with NaOH (1 eq) in EtOH and stirred for 1 hour at room temperature, aldehyde (1 eq) was added and stirred overnight, imidate (1 eq) was prepared and added in one portion..sup.5 The reaction was stirred overnight, was then quenched by water and extracted with DCM. The organic fraction was collected and dried in vacuo. Compounds were further purified by flash chromatography (50% Ethyl Acetate, 50% Hexanes) to yield 1/2/5.
[0093] 1: (Z)-tert-butyl 2-(4-(4-(hydroxy)benzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetate. Crystalline orange solid. .sup.1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J=8.9, Hz, 2H), 6.95 (s, 1H), 6.85 (d, J=8.9 Hz, 2H), 4.40 (m, 3H), 2.27 (s, 3H), 1.44 (s, 9H). .sup.13C NMR (126 MHz, Chloroform-d) δ 167.75, 161.59, 160.23, 135.95, 134.76, 126.91, 125.62, 116.27, 82.60, 42.32, 28.07, 15.53. [M+H]+: Calcd, 317.3570, Obsd, 317.1495
[0094] 2: (Z)-tert-butyl 2-(4-(4-(dimethylamino)benzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetate. Crystalline orange solid. .sup.1H NMR (500 MHz, Chloroform-d) δ 8.07 (d, J=8.9 Hz, 2H), 7.11 (s, 1H), 6.70 (d, J=8.8 Hz, 2H), 4.29 (s, 2H), 3.05 (s, 6H), 2.31 (s, 3H), 1.48 (s, 9H). .sup.13C NMR (126 MHz, Chloroform-d) δ 170.11, 166.90, 158.03, 151.56, 134.27, 134.22, 129.41, 122.19, 111.72, 82.83, 42.15, 40.04, 27.99, 15.43. [M+H]+: Calcd, 344.1896, Obsd, 344.1983
[0095] 5: (Z)-tert-butyl 2-(4-benzylidene-2-methyl-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetate. Crystalline yellow solid. H NMR (500 MHz, Chloroform-d) δ 8.05 (d, J=8.8, Hz, 2H), 7.30 (m, 3H), 7.01 (s, 1H), 4.19 (s, 2H), 2.23 (s, 3H), 1.39 (s, 9H). [M+H]+: Calcd, 301.3580, Obsd, 301.3367
##STR00260## ##STR00261##
[0096] Scheme 2. General protocol for synthesis of in vitro GFP mimic probe. Carbon-carbon double bond formation via aldol condensation. Conditions, aldehyde (2eq), 2 or 5 (1 eq) were combine in dioxane under Argon. ZnCl.sub.2 (0.01 eq) was added and the reaction was refluxed overnight. Solvent was removed and compounds were purified by flash chromatography (2:5, EA:Hexanes) to yield final GFP mimic probes 3/3a/3b.
[0097] 3: tert-butyl 2-((Z)-4-(4-(dimethylamino)benzylidene)-2-((E)-4-(dimethylamino)styryl)-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetate. Red Solid. .sup.1H NMR (500 MHz, Chloroform-.sup.d) δ 8.19 (d, J=8.6 Hz, 2H), 7.97 (d, J=15.6 Hz, 1H), 7.48 (d, J=8.7, 2H), 6.75 (d, J=8.6, 2H), 6.70 (d, J=8.6, 2H), 6.42 (d, J=15.6 Hz, 1H), 4.45 (s, 2H), 3.07 (d, J=15.1 Hz, 12H), 1.49 (m, 9H). 13C NMR (126 MHz, Chloroform-d) δ 170.36, 167.11, 156.60, 151.43, 151.34, 149.45, 139.93, 135.54, 134.83, 134.30, 132.48, 129.40, 129.17, 127.63, 123.53, 123.21, 112.91, 111.95, 111.85, 111.71, 107.58, 82.72, 60.39, 42.79, 42.37, 40.17, 40.11, 40.03, 31.24, 29.71, 28.03, 27.98, 21.06, 14.21. [M+H]+ Calcd, 475.2664, Obsd, 475.3517
[0098] 3a: tert-butyl 2-((Z)-4-benzylidene-2-((E)-4-(dimethylamino)styryl)-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetate. Red oil. .sup.1H NMR (500 MHz, Chloroform-d) δ 8.25 (d, J=8.5, 2H), 8.15 (d, J=15.6 1H), 7.56-7.50 (m, 2H), 7.46 (t, J=7.6 Hz, 2H), 7.41-7.37 (m, 1H), 7.12 (s, 1H), 6.75 (d, J=8.6, 2H), 6.41 (d, J=15.5 Hz, LH), 4.46 (d, J=8.8 Hz, 2H), 3.07 (s, 6H), 1.50 (s, 9H). .sup.1C NMR (126 MHz, Chloroform-d) δ 171.14, 170.53, 166.78, 159.80, 151.79, 142.13, 139.38, 134.98, 132.96, 132.37, 132.31, 132.18, 129.88, 129.67, 129.62, 128.64, 128.56, 125.54, 123.02, 111.89, 110.99, 106.56, 82.98, 60.39, 42.34, 40.13, 34.67, 34.53, 31.65, 31.59, 29.71, 29.06, 28.00, 27.96, 25.28, 22.66, 21.10, 21.05, 20.70, 14.20, 14.12, 11.43. [M+H]+ Calcd, 432.2242, Obsd, 432.2269
[0099] 3b: tert-butyl 2-((Z)-4-(4-(dimethylamino)benzylidene)-5-oxo-2-((E)-styryl)-4,5-dihydro-1H-imidazol-1-yl)acetate. Red solid. .sup.1H NMR (500 MHz, Chloroform-d) δ 8.20 (d, J=8.7 Hz, 2H), 8.01 (d, J=15.8 Hz, 1H), 7.65-7.57 (m, 2H), 7.42 (tt, J=8.5, 4.1 Hz, 3H), 7.20 (s, 1H), 6.80 (d, J=8.7, 2H), 6.68 (d, J=15.8 Hz, 1H), 4.47 (s, 2H), 3.10 (s, 6H), 1.48 (s, 911). .sup.13C NMR (126 MHz, Chloroform-d) δ 170.11, 166.99, 155.57, 151.68, 139.12, 135.56, 135.04, 134.71, 129.72, 129.70, 128.94, 127.67, 122.82, 113.34, 111.84, 82.92, 67.10, 42.33, 40.10, 29.72, 27.98.
##STR00262##
[0100] Scheme 3. Synthesis of PEG linker in large scale. Commercially available chloro-alcohol was converted into tosylate. Condition (a) 6-Chloro-1-hexanol (1.0 eq.), p-Toluenesulfonyl chloride (1.1 eq), 4-dimethylaminopyridine (0.1 eq) in pyridine for 1.5 hours at 0° C. The reaction mixture was extracted with diethyl ether against diluted HCl. The organic phase was collected and evaporated under reduced pressure, yielding crude colorless crystal 6. The product was carried on to the next step without further purification. Commercially available amino-alcohol was protected with t-butyl carbonate group. Condition (b) 2-(2-Aminoethoxy)ethanol (1.0 eq.), Di-tert-butyl dicarbonate (1.0 eq.) in methanol stirred for 3 h at room temperature. The reaction mixture was extracted with PBS Buffer against dichloromethane. The organic fraction was dried in vacuo. Compounds were further purified by flash chromatography (1:1 ethyl acetate/hexane) to yield 7, a colorless oil. 6 and 7 were combined to become protected PEG linker. Condition (c) 6 (1 eq), 7 (1.1 eq), and Potassium tert-butoxide (1 M in THF, 1.5 eq) in DMF stirred overnight at room temperature. The reaction was quenched with water and extracted with diethyl ether. The product was further purified by flash chromatography (1:2 ethyl acetate: hexane). Colorless oil 8 was obtained. Deprotection of 8 yielded the PEG amine hydrochloride. Condition (d) 8 (1 eq), HCl (4 M in Dioxane, 6 eq) stirred for 1 h at room temperature. Concentrated and then dried under high-vac to yield 9 a white solid.
[0101] 6: 6-chlorohexyl 4-methylbenzenesulfonate. Colorless Crystal. (R.sub.1=0.55, 1:9 EA:Hexane). .sup.1H NMR (500 MHz, CDCl.sub.3) δ 7.73 (d, J=8.3 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 3.97 (t, J=6.4 Hz, 2H), 3.43 (t, J=6.6 Hz, 2H), 2.39 (s, 3H), 1.73-1.54 (m, 4H), 1.39-1.24 (m, 4H). .sup.13C NMR (126 MHz, CDCl.sub.3) δ 144.73, 132.99, 129.81, 127.73, 70.37, 44.75, 32.19, 28.54, 26.05, 24.57, 21.51. [M+Na]+: Calcd, 313.0641, Obsd, 313.0639.
[0102] 7: tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate. Colorless oil. .sup.1H NMR (500 MHz, CDCl.sub.3) δ 5.29 (s, 1H), 3.73-3.64 (m, 2H), 3.56-3.45 (m, 4H), 3.31-3.15 (m, 3H), 1.45-1.34 (m, 9H). .sup.1C NMR (126 MHz, CDCl3) δ 156.26, 79.30, 72.32, 70.31, 61.55, 40.37, 28.42. HRMS for [M+Na]+: Calcd, 228.1212, Obsd, 228.1220.
[0103] 8: tert-butyl (2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamate. Colorless oil. .sup.1H NMR (500 MHz, CDCl.sub.3) δ 5.02 (s, 1H), 3.58-3.47 (m, 8H), 3.42 (t, J=6.6 Hz, 2H), 3.30-3.24 (m, 2H), 1.78-1.70 (m, 2H), 1.60-1.53 (m, 2H), 1.46-1.38 (m, 11H), 1.38-1.30 (m, 2H). 13C NMR (126 MHz, CDCl.sub.3) δ 156.03, 79.12, 71.28, 70.28, 70.22, 70.06, 45.02, 40.37, 32.56, 29.46, 28.44, 26.70, 25.44. [M+Na]+: Calcd, 346.1761, Obsd, 346.1765.
[0104] 9: 2-(2-((6-chlorohexyl)oxy)ethoxy)ethanamine hydrochloride. White solid. .sup.1H NMR (500 MHz, DMSO) δ 8.26 (s, 3H), 3.65-3.58 (m, 4H), 3.56-3.52 (m, 2H), 3.51-3.46 (m, 2H), 3.36 (t, J=6.6 Hz, 2H), 2.94-2.87 (m, 2H), 1.73-1.65 (m, 2H), 1.51-1.44 (m, 2H), 1.41-1.33 (m, 2H), 1.33-1.25 (m, 2H). .sup.1C NMR (126 MHz, DMSO) δ 70.23, 69.70, 69.34, 66.58, 45.39, 38.37, 32.03, 29.06, 26.13, 24.93. [M+H]: Calcd, 224.1417, Obsd, 224.1411.
##STR00263##
[0105] Scheme 4. Synthesis of rigid linker for small molecule probe. Commercially available cyclohexane linker was coupled with homemade PEG linker. Condition (e) 9 (1 eq.), trans-4-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclohexanecarboxylic acid (1 eq.), dimethylaminopyridine (0.1 eq.), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2 eq.) in triethylamine (4 eq.) stirred overnight at room temperature. The reaction mixture was quenched by water and extracted with DCM. Product was purified by flash chromatography (100% ethyl acetate). Sticky white solid 10 was obtained. Deprotection was of 10 yields final rigid linker amine hydrochloride. Condition (D 10 (1 eq.), in HCl (4 M in Dioxane, 6 eq.) for 1 h at room temperature. Reaction was concentrated and put under high-vac to yield fluffy white solid 11.
[0106] 10: tert-butyl ((1r,4r)-4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)carbamoyl)cyclohexyl)carbamate. Sticky white solid. .sup.1H NMR (500 MHz, CDCl.sub.3) δ 5.99 (s, 1H), 4.45-4.38 (m, 1H), 3.61-3.49 (m, 8H), 3.47-3.37 (m, 5H), 2.10-2.03 (m, 2H), 2.01-1.95 (m, 1H), 1.93-1.85 (m, 2H), 1.79-1.71 (m, 2H), 1.62-1.51 (m, 4H), 1.47-1.40 (m, 11H), 1.39-1.32 (m, 2H), 1.13-1.03 (m, 2H). .sup.1C NMR (126 MHz, CDCl.sub.3) δ 175.29, 155.23, 79.23, 71.32, 70.30, 70.07, 69.86, 49.13, 45.10, 44.63, 39.06, 32.80, 32.58, 29.54, 28.49, 26.75, 25.48. [M+H].sup.+: Calcd, 449.2782, Obsd, 449.2783.
[0107] 11: (1r,4r)-4-amino-N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)cyclohexanecarboxamide hydrochloride. Fluffy white solid. .sup.1H NMR (500 MHz, DMSO) δ 8.19 (s, 3H), 7.87 (s, 1H), 3.61 (t, J=6.6 Hz, 2H), 3.52-3.43 (m, 4H), 3.40-3.33 (m, 4H), 3.20-3.13 (s, 2H), 2.96-2.87 (m, 1H), 2.11-2.03 (m, 1H), 2.01-1.94 (m, 2H), 1.78-1.65 (m, 4H), 1.53-1.43 (m, 2H), 1.43-1.25 (m, 8H). .sup.1C NMR (126 MHz, DMSO) δ 174.43, 70.18, 69.59, 69.45, 69.07, 48.75, 45.39, 42.46, 38.39, 32.03, 29.43, 29.07, 27.19, 26.12, 24.94. [M+H].sup.+: Calcd, 349.2258, Obsd, 349.2257.
##STR00264##
[0108] Scheme 5. Synthesis of GFP mimic precursors with rigid Halo linker. Deprotection of GFP core. Condition (a) 2 deprotected according to literature protocols to yield 12 which was used without further purification. GFP core was coupled with rigid Halo linker. Condition (b) 2 (1 eq), 11 (1.0 eq), dimethylaminopyridine (0.1 eq), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.0 eq), triethylamine (4.0 eq), overnight, RT. The reaction mixture was quenched by water and extracted with DCM. The organic fraction was collected and dried in vacuo. Compounds were further purified by flash chromatography (20:1, DCM:MeOH) to yield 13 a yellow powder.
[0109] 13: (1r,4r)-N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-4-(2-((Z)-4-(4-(dimethylamino)benzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetamido)cyclohexanecarboxamide. Yellow powder. .sup.1H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J=8.8 Hz, 2H), 7.14 (s, 1H), 6.73 (d, J=8.9 Hz, 2H), 6.17-5.87 (m, 2H), 4.23 (s, 2H), 3.60-3.40 (m, 10H), 3.09 (s, 6H), 2.40 (s, 3H), 2.10-1.32 (m, 18H), 1.22-1.09 (m, 2H). .sup.13C NMR (126 MHz, Chloroform-d) δ 174.99, 170.56, 166.29, 157.54, 151.88, 134.58, 133.55, 130.56, 121.83, 111.76, 71.26, 70.24, 69.99, 69.80, 48.20, 45.07, 44.76, 44.36, 40.05, 39.01, 32.51, 32.03, 29.45, 28.25, 26.68, 25.40, 15.59. [M+H].sup.+: Calcd, 618.3344, Obsd, 618.3441.
##STR00265##
[0110] Scheme 6. Protocol for synthesis of in vivo GFP mimic probe. TBDMS protection. Conditions (a) 4-[Bis(2-hydroxyethyl)amino]benzaldehyde (1.0 eq) and imidazole (4.2 eq) were combined in DMF at room temperature, chloro(1,1-dimethylethyl)dimethylsilane (2.2 eq) was added and stirred for 1.5 hours. The reaction mixture was quenched with IM HCl and extracted with ether. The organic fraction was collected and dried in vacuo to yield 14 a transparent brown oil, product was used without further purification. Carbon-carbon double bond formation via aldol condensation. Conditions (b) 14 (2.0 eq), 13 (1.0 eq) were combine in in dioxane under Argon. ZnCl.sub.2 (0.01 eq) was added and the reaction was refluxed overnight. Solvent was removed and compounds were purified by flash chromatography (20:1, DCM:MeOH) to yield 15. Product was immediately deprotected. Conditions (1) 15 (1.0 eq) was combined with TBAF (3.0 eq) in THF and stirred overnight. Compounds were purified by flash chromatography (10:1, DCM:MeOH) to yield 4 a pink solid.
[0111] 4: (1r,4r)-4-(2-((Z)-2-((E)-4-(bis(2-hydroxyethyl)amino)styryl)-4-(4-(dimethylamino)benzylidene)-5-oxo-4,5-dihydro-1H-imidazol-1-yl)acetamido)-N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)cyclohexanecarboxamide. Pink solid. .sup.1H NMR (500 MHz, DMSO-d6) δ 8.17 (d, J=8.3 Hz, 2H), 7.79 (d, J=15.5 Hz, 1H), 7.55 (d, J=8.7 Hz, 2H), 6.84 (s, 1H), 6.80 (dd, J=9.9, 2.7 Hz, 2H), 6.75 (dd, J=8.6, 5.5 Hz, 2H), 6.66 (d, J=15.5 Hz, 1H), 4.82 (s, 2H), 4.38 (s, 2H), 3.59-3.43 (m, 12H), 3.41-3.35 (m, 6H), 3.20-3.13 (m, 2H) 3.04 (s, 6H), 2.12-1.17 (m, 18H). .sup.13C NMR (126 MHz, DMSO-d6) δ 175.24, 170.22, 166.39, 158.07, 151.49, 150.02, 139.33, 135.98, 134.26, 130.23, 125.20, 122.97, 122.84, 112.28, 111.89, 111.42, 108.29, 70.64, 70.04, 69.90, 69.55, 58.67, 58.60, 58.43, 53.59, 49.07, 48.09, 45.83, 43.53, 42.65, 38.85, 32.48, 32.07, 29.54, 28.61, 26.59, 25.40, 13.99. [M+H]+ Calcd, 809.4357, Obsd, 809.4369.
[0112] Examples of Application
[0113] Examples provided herein are indicative of, but should not be construed as limiting of, the overall invention.
[0114] Protein aggregation is a multistep process that includes aberrant conformations in the form of soluble oligomers, disordered or amorphous aggregates, and amyloid fibrils containing ordered hydrogen-bonded β-sheet structures. Embodiments provide methods for detecting proteins as misfolded oligomers, insoluble aggregates, and amyloid fibers. Principle of detection includes providing disclosed compounds (fluorescent protein chromophores) that fluoresce when placed in an environment of enhanced rigidity indicative of protein aggregation in a local microenvironment. In a typical embodiment fluorescence occurs when the rigid microenvironment causes inhibition of non-radiative decay via twisted-intramolecular charge transfer (TICT). This principle can be applied to detection conducted in test tubes and live cells.
[0115] Detection as reported herein may be conducted using purified proteins in test tubes or in live cells bearing proteins of interest.
[0116] In one embodiment, protein aggregation and protein misfolding are detected by disclosed compounds in test tubes. This detection can be conducted with or without covalent conjugation to proteins of interest. Normally, purified proteins are used in this detection. These proteins are subjected to in vitro conditions to induce protein misfolding and aggregation. Disclosed compounds can be added before, during, or after protein misfolding and aggregation. Fluorescence intensity can be recorded by fluorescence spectrophotometers or fluorescence microplate readers.
[0117] In one embodiment, aggregation of proteins of interest is detected in live cells either transiently or stably expressing these proteins. The inventors disclose the compounds with the following methods (varying R.sub.3 groups) to conjugate with proteins of interest that are of at least one of the aberrant conformations in the form of soluble oligomers, disordered or amorphous aggregates, and amyloid fibrils containing ordered hydrogen-bonded β-sheet structures. These compounds can covalently conjugate with the Halo-Tag fusion domain (a product from Promega Inc) via a chloroalkane linker, the SNAP-Tag fusion domain (a product from NEB Inc.) via an O6-benzylguanine linker, the CLIP-Tag fusion domain (a product from NEB Inc.) via an O6-benzylcytosine linker, exposed cysteine via maleimide, or exposed lysine via N-Hydroxysuccinimide (Succinimidyl) esters. Fluorescence detection can be conducted by fluorescence spectrophotometers, fluorescence microplate readers, and epifluorescence or confocal fluorescence microscopes.
[0118] In one embodiment, aggregation of cellular proteins is detected in live cells. The inventors disclose the compounds with the following methods (varying R.sub.3 groups) to bind to cellular proteins that are of at least one of the aberrant conformations in the form of soluble oligomers, disordered or amorphous aggregates, and amyloid fibrils containing ordered hydrogen-bonded β-sheet structures. These compounds can non-covalently bind to these conformations using a thioflavin-T guiding group or a tert-Butyloxycarbonyl guiding group. Fluorescence detection can be conducted by fluorescence spectrophotometers, fluorescence microplate readers, and epifluorescence or confocal fluorescence microscopes.
[0119] Applications as reported above can also be conducted in fixed cell samples with or without permeabilized cellular membranes.
[0120] Embodiments further provide a kit for detecting at least one of the following aberrant protein conformations: misfolded oligomers, amorphous insoluble protein aggregates, amyloid fibrils containing ordered hydrogen-bonded β-sheet structures. The kit includes the following components: one or more of disclosed fluorescent protein chromophores as reported herein of a known concentration in stock solutions of Dimethyl Sulfoxide or Ethanol, one or more standard protein samples that form one of the abovementioned aberrant protein conformations, and optionally, instructions for use in detecting at least one of one of the abovementioned aberrant protein conformations.
[0121] Compounds Detecting Misfolded Oligomers in Test Tubes (AggGlow Method).
[0122] The inventors have designed and synthesized an HBI analogue, 3, which harbors an extended π conjugation to both increase QY and restrict bond rotation (
[0123] Determination of Compound 3's detection of protein aggregation via fluorescence increase (
[0124] Compound 3 was also used to monitor kinetics of α-syn aggregation. Purified α-syn typically aggregates via a three-step process: formation of soluble oligomers, growth of amyloid fibers, and maturation of fibers (
[0125] In addition to α-synuclein, Compound 3 may detect aggregates formed by globular proteins, by using mutant superoxide dismutase 1 (SOD1), whose aggregation is commonly found in ALS disease. The recently discovered SOD1(V31A) mutant may be used to confirm this. After 20 min incubation at 59° C., an 8 to 10-fold fluorescence intensity increase (
[0126] 3 detects soluble oligomers via fluorescence increase. To test this point, the inventors chose α-synuclein (α-syn), whose aggregation is associated with Parkinson's disease..sup.42 Purified α-syn aggregates via a three-step process: formation of soluble oligomers, growth of amyloid fibers, and maturation of fibers (
[0127] Compounds Detecting Misfolded Oligomers in Live Cells (AggGlow Method).
[0128] 3 is used to monitor stress-induced proteome aggregation in HEK293T (human embryonic kidney) cells with a proteasome inhibitor MG132. Inhibition of proteasome has been shown to form cytosolic misfolded oligomers and insoluble aggregates of cellular proteins. When 5 μM of MG132 was used to treat HEK293T cells in the presence of 2.5 μM 3, obvious fluorescence pattern was developed in the cytosol of cells as a result of proteasome inhibition (
[0129] Compounds Detecting Misfolded Oligomers of Specific Proteins in Live Cells (AggTag method).
[0130] The inventors further examined using a turn-on fluorescence to monitor aggregation of a protein-of-interest (POI) using in live cells. For this example, the inventors genetically fused Halo-Tag to the POI and synthesized 4 for bioorthogonal conjugation (
[0131] Using the AggTag method, the inventors expected that the fluorophore should remain dark when POI is folded. Aggregation of POI, however, should bury the fluorophore in protein aggregates that can restrict its rotation and trigger fluorescence (
[0132] To test whether 4 is fluorogenic upon protein aggregation in live cells, an experiment was conducted using the Huntingtin exon 1 protein (Htt) with expansion of a polyglutamine tract within its N-terminal domain, well known for its severe protein aggregation. The inventors first observed protein aggregation using conventional non-fluorogenic methods (
[0133] Thus, protein aggregation is primarily judged by the appearance of fluorescent puncta in non-fluorogenic methods (
[0134] This fluorescence was not due to non-specific binding of 4 in cells, because HEK293T cells expressing Htt-97Q without Halo-Tag showed no fluorescent signal (
[0135] Experiments further demonstrated that the AggTag method could visualize previously invisible misfolded soluble proteins in live cells. The SOD1(V31A) mutant is associated with a slow disease progression. So far, little had been known about its aggregation propensity in live cells. To this end, the inventors expressed and labeled SOD(V31A)-Halo fusion protein simultaneously with the coumarin ligand and 4 in HEK293T cells. Using the coumarin fluorescence, the inventors found that SOD1(V31A) was primarily located in the cytoplasm and the oxidative stress inducer NaAsO.sub.2 induced the partial translocation of SOD1(V31A) to the nucleus. Although these observations are consistent to previously reported cellular locations of other SOD1 mutants, it was unclear whether NaAsO.sub.2 caused aggregation because the coumarin fluorescence remained diffuse before and after stress (left panel,
[0136] The punctate fluorescence could be rationalized by a fractionation experiment wherein more aggregates of SOD1(V31A) were found in cells treated with NaAsO.sub.2 (
[0137] Cellular Background and Control Experiments of Oligomer-Detecting Compounds.
[0138] A series of control experiments were carried out to demonstrate that the turn-on fluorescence specifically monitors misfolding of POIs. First, 4 fluorescence was not observed in cells expressing Halo-Tag in the presence of the NaAsO.sub.2 stressor (50 M, 18 h, 37° C.). Second, HEK293T cells co-expressing Htt-Q97-GFP and Halo-Tag or just expressing Htt-Q97 showed no fluorescence of 4. Third, turn-on fluorescence was not observed in cells co-expressing Halo-Tag and SOD1-V31A-GFP in the presence of the NaAsO.sub.2 stressor (50 μM, 18 h, 37° C.). These control experiments collectively demonstrate that the observed fluorescent signal from 4 was not due to non-specific binding between 4 and aggregates of other cellular proteins in cells.
[0139] Compounds Detecting Insoluble Aggregates in Test Tubes (AggTag Method).
[0140] 2 only activates fluorescence when POI forms insoluble aggregates, while it remains dark when POI is folded and forms soluble oligomers. The inventors installed Halo-tag reactive warhead to 2, resulting in 5. In heat-induced aggregation of SOD1-A4V-Halo that is conjugated to 5, it was found that the kinetics of P2b fluorescence increase was similar to that of turbidity whose signal originates from insoluble aggregates (green vs black curve,
[0141] Compounds Detecting Insoluble Aggregates of Specific Proteins in Live Cells (AggTag Method).
[0142] It is important to distinguish insoluble aggregates from misfolded oligomers, because they do not only have distinct functions in cells, but also are managed differently by cells..sup.46,47 Soluble oligomers are targeted to the Juxta-Nuclear Quality (JUNQ) control compartment, which forms under severe stress conditions and contains polyubiquitylated proteins, such as mutants of SOD1. In contrast, insoluble aggregates, such as polyglutamine-expanded Huntingtin (Htt-polyQ), are sequestered into a cytoplasmic compartment known as the Insoluble Protein Deposit (IPOD). Thus, misfolded oligomers do not necessarily display as a diffusive structure, instead they can reside in granular structures that appear to be almost identical to granules formed by insoluble aggregates.
[0143] The spectra of 4 (E.sub.x/E.sub.m=530/600 nm;
[0144] Combination of 4 and 5 enables a two-color imaging strategy to differentiate insoluble aggregates from soluble oligomers. The inventors carried out live cell imaging experiments, wherein 4 or 5 was used to visualize aggregation of POI-Halo fusion proteins in HEK293T cells. Under proteasome inhibition by a drug MG132, mutants of SOD1 has been shown to form JUNQ compartments that contain soluble oligomers..sup.47 If this were true, it would be expected that granules exhibit turn-on fluorescence with 4 but not 5. To this end, the inventors labeled HEK293T cells expressing SOD1-A4V-Halo simultaneously with 4 and 5 (both at 0.5 μM) for 24 h and treated cells with 5 μM MG132 for 8 h. As expected, SOD1 A4V-Halo formed mostly perinuclear granules that only exhibited red fluorescence from 4 (
[0145] Cellular Background and Control Experiments of Insoluble Aggregates-Detecting Compounds.
[0146] As a control, 5 fluorescence was not observed in cells co-expressing Halo-tag and Htt-110Q-mChery (
[0147] Compounds Enable Bioconjugation to Halo-Tag and SNAP-Tag Fusion Proteins (AggTag Method).
[0148] Halo-Tag is an engineered dehalogenase that reacts with chloroalkane molecules to form stable covalent enzyme-ligand conjugates, and it serves as an ideal sensor platform because it exhibits fast labeling kinetics, a bioorthogonal reaction profile, and demonstrated evolvability.sup.48,49. SNAP-tag is a prominent self-labelling protein tag used for live cell imaging of POIs, due to its relatively small size (19.4 kDa, two-thirds the size of GFP as 27 kDa) and fast labelling kinetics..sup.50-53
[0149] Probes can be developed to detect aggregation of POI fused with SNAP-tag. Using 3 as the fluorophore (
[0150] Experimental Methods
[0151] Plasmids. Mammalian expression: pHTN vector (Promega, Inc) with a stop codon added to the c-terminal of Halo-Tag protein. The SOD-1 gene was amplified from the pF146 pSOD1WTAcGFP1 (a gift from Elizabeth Fisher, Addgene plasmid #26407), respectively. The V31A mutation was introduced to SOD1 via QuickChange PCR. The Htt-97Q gene was amplified from the pCDNA3.1-Htt-97Q-mCherry (Max Planck Institute of Biochemistry). These genes were sub-cloned into a pHTC HaloTag CMV-neo vector by the PIPE cloning method. Protein expression: pET29b vectors were constructed to encode Halo-Tag-His6, SOD1(V31A)-linker-Halo-His6 (linker contains a TEV protease cleavage site), and α-synuclein.
[0152] Protein expression and purification. Halo-Tag and SOD1(V31A)-Halo: E. coli BL21 DE3* competent cells harboring a pBAD vector encoding σ32-I54N were transformed with pET29b vectors containing Halo-His6 and SOD1(V31A)-TEV-Halo-His6 proteins. Expression and purification was carried out as previously described. In brief, cells expressing recombinant proteins were thawed and lysed by sonication at 4° C. in the presence of a protease inhibitor (1 mM PMSF). Lysed cells were centrifuged for 60 min at 16,000×g. The supernatant was collected and loaded onto a 6 mL BioRad Nuvia Ni-IMAC column and washed with 120 mL of buffer containing 50 mM Tris.Math.HCl (pH 7.5) and 100 mM NaCl. The protein was then eluted by gradient addition of buffer containing 50 mM Tris.Math.HCl(pH 7.5), 100 mM NaCl, and 500 mM imidazole over a volume of 48 mL. The protein fractions were identified by SDS-PAGE analysis, pooled, and concentrated. The protein was further purified using a 120 mL HiPrep™ 16/60 Sephacryl™ S-200 HR size-exclusion column. The protein containing fractions were identified by SDS-PAGE gel analysis, pooled, and concentrated. No significant impurities were identified and purity was estimated to be >98% based on SDS-PAGE. SOD1(V31A): Purified SOD1(V31A)-Halo protein was subjected to a 1 h TEV protease cleavage (0.50 μM TEV protease for every 10 μM SOD1-Halo protein) in the presence of 1 mM DTT at 25° C. Reaction mixture was retro-purified via BioRad Nuvia Ni-IMAC resin. Flow through was collected as cleaved SOD1(V31A). No significant impurities were identified and Halo purity was estimated to be >98% based on SDS-PAGE. α-synuclein: Protein expression was induced with 0.1 M IPTG, 5 hours, 37° C. Harvest culture at 5,000 RPM, 15 min, 4° C. Resuspend the pellet in DPBS (200 mg/L KCl, 200 mg/L KH.sub.2PO.sub.4, 8 g/L NaCl, 2.16 g/L Na.sub.2HPO.sub.4.7H.sub.2O), transfer to a 50 mL conical tube. Spin at 4,000 rpm, 30 min, 4° C. Decant the supernatant, and store the pellet in a −80° C. freezer. Next morning, resuspend defrosted pellet in osmotic shock buffer (30 mM Tris-HC, 40% sucrose, 2 mM EDTA, pH 7.5; 100 mL for each liter of starter culture). Incubate for 10 min at room temperature. Collect pellet by centrifugation (12,000 rpm, 20 min). Quickly resuspend pellet with ice-cold water (90 mL for each liter of starter culture). Add 4 M MgCl.sub.2 (76.5 μl for each liter of starting culture) and keep on ice for 3 min. Centrifuge at 15,000 rpm, 30 min. Collect and filter supernatant. Add 2 M Tris-HC, pH 8 at a 1:100 (v/v) ratio. Load supernatant onto UNO Sphere Q column (5 mL, Bio-Rad), elute with a gradient from Buffer A (20 mM Tris, pH 8) to Buffer B (20 mM Tris, 500 mM NaCl, pH 8). Analyze fractions by 15% SDS-PAGE gel. Pool protein-containing fractions, and dilute by half with degassed Buffer A. Centrifuge at 15,000 rpm, 30 min to remove aggregates. Load onto an EnrichQ column (8 mL) on the NGC-Quest10 FPLC system and elute with a gradient from 0% to 100% Buffer B. Analyze fractions by 15% SDS-PAGE gel. Pool protein-containing fractions and dilute by half with degassed Buffer A. Load onto an EnrichQ column (8 mL) and elute with a gradient from 40% to 52% Buffer B. Analyze fractions by 15% SDS-PAGE gel. Pool protein containing fractions and flash freeze small aliquots of protein. Proteins can only be thawed once before use.
[0153] Confocal microscope imaging. The HEK293T cells were seeded at 25% confluency 24 h prior to transfection in poly-D-lysine coated 35 mm glass bottom dishes (MatTek Corporation). Cells were grown in DMEM media supplemented with 10% FBS and Penicillin-Streptomycin antibiotics until they reached 50-60% confluency. Transfection was carried out using X-tremeGene™ 9 DNA transfection reagent (Roche) according to the manufacturer's instructions. Proteins were expressed for 24 h prior to analyses. To label proteins with Halo-Tag fusion, protein expression was carried out in the presence of 1 μM 4 or 1 μM TMR Halo-Tag ligand to form covalent conjugate with the Halo-Tag domain. For a dual-probe labeling scheme, 1 μM 4 and 1 μM coumarin Halo-Tag ligand to simultaneously form covalent conjugate with the Halo-Tag domain.
[0154] To wash off unbound Halo ligands, the cells were washed extensively by replacing media with fresh DMEM and incubating for 30 min at 37° C. For confocal fluorescence imaging with either 4-labeled Halo fusion, TMR-labeled Halo fusion, EGFP fusion, or mCherry fusion proteins, DMEM media was replaced with FluoroBrite™ DMEM media (ThermoFisher) supplemented with 10% FBS, and Hoechst 33342 (0.1 μg/mL). For confocal fluorescence imaging with either dual-probe labeled Halo fusion with 4 and coumarin ligand, DMEM media was replaced with FluoroBrite™ DMEM media (ThermoFisher) supplemented with 10% FBS. The samples were incubated for 30 min prior to imaging. Media was replaced with fresh FluoroBrite™ DMEM media (ThermoFisher) supplemented with 10% FBS prior to imaging. Confocal images were obtained using Olympus FluoView™ FV1000 confocal microscope. The EGFP fluorescence was visualized using blue argon (488 nm) laser. Nuclear staining and coumarin fluorescence was visualized using violet laser (405 nm). Fluorescence of TMR and 4 were visualized using green HeNe laser (543 nm).
[0155] Chemical-Induced Proteome Stress and Confocal Imaging of Stressed Cells.
[0156] HEK293T cultures were seeded at 25% confluency 24 h prior to transfection in 12-well plate for time dependent fluorescence plate reader analysis or 35 mm glass bottom culture dishes (Poly-d-lysine coated, MatTek Corporation). Cells were grown in DMEM medium supplemented with 10% FBS and penicillin-streptomycin antibiotics until they reached 50-60% confluency. Transfection was performed using X-tremeGene™ 9 DNA transfection reagent (Roche). After 24 h of protein expression and co-translational labeling, medium was replaced with fresh DMEM to diffuse out unbound ligands. After 30 min, media was replaced by fresh DMEM medium containing DMSO vehicle or NaAsO.sub.2 (50 μM). Cells were incubated for 18 h, 37° C. in a CO.sub.2 incubator. Nuclear stain Hoechst 33342 (0.1 g/mL) was added to the medium 30 min prior to confocal imaging. Aggregation Assays. α-synuclein: Aggregation solution contained 70 or 140 μM α-synuclein in 20 mM HEPES (pH 7.5) and 100 mM NaCl. 10 μM of 3 or ThT was added to the solution at the beginning of reaction. Previous studies have shown that the kinetics of α-synuclein aggregation is unaffected by the addition of ThT. A volume of 150 μL of the mixture was pipetted into a well of clear-bottom 96-well plate, which was subsequently sealed with Mylar plate sealers. The plate was loaded on a Heidolph vibrating platform shaker and shake at 1,350 rpm at 37° C. At indicated time points, fluorescence reading was obtained using a Tecan M1000Pro fluorescence plate reader. Fluorescence intensity was recorded at E.sub.x=530 nm/E.sub.m=600 nm for 3 and E.sub.x=450 nm/E.sub.m=480 nm for ThT. Each sample was run in triplicate or quadruplicate. SOD1(V31A): Aggregation was carried out with DPBS buffer containing indicated concentrations of EDTA that is used to chelate the structural metal of SOD1. Aggregation solution contained 42 μM SOD1(V31A) or SOD1(V31A)-Halo and 21 M of 3 was added to the solution at the beginning of reaction. Reaction was carried out quiescently at indicated temperatures. Fluorescence of 3 was measured at E.sub.x=530 nm/E.sub.m=600 nm.
[0157] X-ray structure determination of 3. Single crystals of 3 (C.sub.28H.sub.34N.sub.4O.sub.3) were grown by evaporation in EtOH and ethyl acetate mixed solvents. A suitable crystal was selected and mounted on a nylon loop, with help of paratone oil on a ‘SMART APEX CCD area detector’ diffractometer (molybdenum target, 1600 kW). The crystal was kept at 243 K during the data collection. Using Olex2.sup.54, the structure was solved with the XS.sup.55 structure solution program using Direct Methods and refined with the XL refinement package using Least Squares minimization without use of any constraints/restraints. The hydrogen atoms were placed geometrically, and rode their parent atoms during the refinement. Crystal Datafor C.sub.28H.sub.3N.sub.4O.sub.3 (M=474.59 g/mol): orthorhombic, space group P2.sub.12.sub.12.sub.1 (no. 19), a=9.895(4) Å, b=21.470(10) Å, c=25.711(12) Å, V=5463(4) Å.sup.3, Z=8, T=243 K, μ(MoKα)=0.076 mm.sup.−1, Dcalc=1.154 g/cm.sup.3, 51829 reflections measured (3.7°≤2Θ≤57.88°), 13915 unique (R.sub.int=0.1226, R.sub.sigma=0.1327) which were used in all calculations. The final R.sub.1 was 0.0570 (>2sigma(I)) and wR.sub.2 was 0.1767 (all data).
[0158] Negative staining electron microscopy. Carbon-coated 400 mesh EM grids supported by Formvar film were plasma-discharged prior to use. A small amount (˜5 L) of sample suspension was applied onto the grids. The grids were then blotted to remove excess of the sample and stained with 1% aqueous uranyl. Images were collected at indicated resolutions.
SUMMARY
[0159] Embodiments as reported herein demonstrate that analogues of FP chromophores can fluoresce in protein aggregates. Different from previous non-fluorogenic methods, methods and compositions, as reported herein, can visualize both misfolded soluble proteins and insoluble aggregates in intact live cells. Such fluorogenic detection can be achieved via chemical modulation of fluorophores with molecular rotor and AIE properties, providing new applications for this large family of molecules. The unique fluorogenicity of this class of probes, combined with the AggTag method, make them generally applicable to a wide range of proteins whose aggregation is associated with diseases and suited to potentiate screening platform to explore therapeutics that can ameliorate aggregation of these pathogenic proteins.
[0160] It will be apparent to those skilled in the art that numerous modifications and variations of the described examples and embodiments are possible in light of the above teachings of the disclosure. The disclosed examples and embodiments are presented for purposes of illustration only. Other alternative embodiments may include some or all of the features of the various embodiments disclosed herein. Therefore, it is the intent to cover all such modifications and alternative embodiments as may come within the true scope of this invention, which is to be given the full breadth thereof. Additionally, the disclosure of a range of values is a disclosure of every numerical value within that range, including the end points.
[0161] Therefore, while certain exemplary embodiments of apparatuses and methods of making and using the same have been discussed and illustrated herein, it is to be distinctly understood that the invention is not limited thereto but may be otherwise variously embodied and practiced within the scope of the following claims. Documents reported herein are incorporated by reference herein; however, if there is a conflict between this document and the incorporated document, this document controls.
[0162] The following documents may be interesting or useful in reviewing and appreciating embodiments as reported herein. Inclusion of these documents is not an admission of any sort. [0163] Grimm, et al., A general method to improve fluorophores for live-cell and single-molecule microscopy. Nat Methods 2015, 12 (3), 244-50, 3 p following 250. [0164] Ando, et al., An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein. Proc Natl Acad Sci USA 2002, 99 (20), 12651-6; Subach, et al., Chromophore transformations in red fluorescent proteins. Chem Rev 2012, 112 (7), 4308-27; Tomura, et al., Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice. Proc Natl Acad Sci USA 2008, 105 (31), 10871-6. [0165] Hong, et al., Aggregation-induced emission. Chem Soc Rev 2011, 40 (11), 5361-88. [0166] Lashuel, et al., The many faces of alphα-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013, 14 (1), 38-48. [0167] Qin, et al., Highly sensitive amyloid detection enabled by thioflavin T dimers. Mol BioSys 2010, 6 (10), 1791-5. [0168] Rosen, et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362 (6415), 59-62. [0169] Dangoumau, et al., Novel SOD1 mutation p.V31A identified with a slowly progressive form of amyotrophic lateral sclerosis. Neurobiol Aging 2014, 35 (1), 266 e1-4. [0170] Los, et al., HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 2008, 3 (6), 373-82; Lin, et al., A Generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling. J Am Chem Soc 2015, 137 (19), 6232-6244; Ballister, et al., Localized light-induced protein dimerization in living cells using a photocaged dimerizer. Nat Commun 2014, 5, 5475. [0171] Gidalevitz, et al., Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311 (5766), 1471-4; DiFiglia, et al., Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277 (5334), 1990-3. [0172] Ramdzan, et al., Tracking protein aggregation and mislocalization in cells with flow cytometiy. Nat Methods 2012, 9 (5), 467-476; Kitamura, et al., Conformational Analysis of Misfolded Protein Aggregation by FRET and live-cell imaging techniques. IntJMolSci 2015, 16 (3), 6076-6092. [0173] Mateju, et al., An aberrant phase transition of stress granules triggered by misfolded protein and prevented by chaperone function. EMBO J 2017, 36 (12), 1669-1687; Zhong, et al., Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. Elfe 2017, 6. [0174] Haidekker, et al., Molecular rotors—fluorescent biosensors for viscosity and flow. Org Biomol Chem 2007, 5(11), 1669-1678; (b) Qian, H; Cousins, M E.; Horak, E. H; Wakefield, A.; Liptak, M D.; Aprahamian, I., Suppression of Kasha's rule as a mechanism for fluorescent molecular rotors and aggregation-induced emission. Nat Chem 2017, 9 (1), 83-87. [0175] Kalaparthi, et al., The nature of ultrabrightness of nanoporous fluorescent particles with physically encapsulated fluorescent dyes. J Mater Chem C 2016, 4 (11), 2197-2210. [0176] Wurth, et al., Relative and absolute determination of fluorescence quantum yields of transparent samples. Nat Protoc 2013, 8 (8), 1535-1550. [0177] Dolomanov, et al., OLEX2: a complete structure solution, refinement and analysis program. J Appl Crystallogr 2009, 42, 339-341. [0178] Sheldrick, G. M., A short history of SHELX. Acta Crystallogr A 2008, 64, 112-122. [0179] Baldridge, et al., Efficient synthesis of new 4-aiylideneimidazolin-5-ones related to the GFP chromophore by 2+3 cyclocondensation of arylideneimines with imidate ylides, Synthesis 2010, 14, 2424-2436.
REFERENCES
[0180] The following references are each relied upon and incorporated herein in their entirety. [0181] [1] Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008) Adapting proteostasis for disease intervention, Science 319, 916-919. [0182] [2] Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., and Kelly, J. W. (2015) Targeting protein aggregation for the treatment of degenerative diseases, Nature reviews. Drug Discovery 14, 759-780. [0183] [3] Labbadia, J., and Morimoto, R. I. (2013) Huntington's disease: underlying molecular mechanisms and emerging concepts, Trends Biochem Sci 38, 378-385. [0184] [4] Kaushik, S., and Cuervo, A. M. (2015) Proteostasis and aging, Nature Medicine 21, 1406-1415. [0185] [5] Olzscha, H., Schermann, S. M., Woerner, A. C., Pinkert, S., Hecht, M. H., Tartaglia, G. G., Vendruscolo, M., Hayer-Hartl, M., Hart, F. U., and Vabulas, R. M. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions, Cell 144, 67-78. [0186] [6] Hipp, M. S., Park, S. H., and Hart, F. U. (2014) Proteostasis impairment in protein-misfolding and -aggregation diseases, Trends in Cell Biology 24, 506-514. [0187] [7] Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and Balch, W. E. (2009) Biological and chemical approaches to diseases of proteostasis deficiency, Annu Rev Biochem 78, 959-991. [0188] [8] Chiti, F., and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human disease, Annu Rev Biochem 75, 333-366. [0189] [9] Aguzzi, A., and O'Connor, T. (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives, Nature Reviews. Drug Discovery 9, 237-248. [0190] [10] Jensen, M. B., and Jasper, H. (2014) Mitochondrial proteostasis in the control of aging and longevity, Cell Metabolism 20, 214-225. [0191] [11] Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300, 486-489. [0192] [12] Haass, C., and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide, Nat Rev Mol Cell Biol 8, 101-112. [0193] [13] Benilova, I., Karran, E., and De Strooper, B. (2012) The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes, Nat. Neurosci. 15, 349. [0194] [14] Kim, Y. E., Hosp, F., Frottin, F., Ge, H., Mann, M., Hayer-Hartl, M., and Hartl, F. U. (2016) Soluble Oligomers of PolyQ-Expanded Huntingtin Target a Multiplicity of Key Cellular Factors, Molecular Cell 63, 951-964. [0195] [15] Ross, C. A., and Poirier, M. A. (2005) What is the role of protein aggregation in neurodegeneration?, Nat. Rev. Mol. Cell Biol. 6, 891. [0196] [16] Gupta, R., Kasturi, P., Bracher, A., Loew, C., Zheng, M., Villella, A., Garza, D., Hartl, F. U., and Raychaudhuri, S. (2011) Firefly luciferase mutants as sensors of proteome stress, Nat Methods 8, 879-884. [0197] [17] Winkler, J., Seybert, A., Konig, L., Pruggnaller, S., Haselmann, U., Soujik, V., Weiss, M., Frangakis, A. S., Mogk, A., and Bukau, B. (2010) Quantitative and spatio-temporal features of protein aggregation in Escherichia coli and consequences on protein quality control and cellular ageing, EMBO J 29, 910-923. [0198] [18] Hsieh, T. Y., Nillegoda, N. B., Tyedmers, J., Bukau, B., Mogk, A., and Kramer, G. (2014) Monitoring Protein Misfolding by Site-Specific Labeling of Proteins In Vivo, PloS one 9. [0199] [19] Ignatova, Z., and Gierasch, L. M. (2004) Monitoring protein stability and aggregation in vivo by real-time fluorescent labeling, P Natl Acad Sci USA 101, 523-528. [0200] [20] Ramdzan, Y. M., Polling, S., Chia, C. P. Z., Ng, I. H. W., Ormsby, A. R., Croft, N. P., Purcell, A. W., Bogoyevitch, M. A., Ng, D. C. H., Gleeson, P. A., and Hatters, D. M. (2012) Tracking protein aggregation and mislocalization in cells with flow cytometry, Nat Methods 9, 467-U476. [0201] [21] Nath, S., Meuvis, J., Hendrix, J., Carl, S. A., and Engelborghs, Y. (2010) [0202] Early aggregation steps in alphα-synuclein as measured by FCS and FRET: evidence for a contagious conformational change, Biophys J 98, 1302-1311. [0203] [22] Wood, R. J., Ormsby, A. R., Radwan, M., Cox, D., Sharma, A., Vopel, T., Ebbinghaus, S., Oliveberg, M., Reid, G. E., Dickson, A., and Hatters, D. M. (2018) A biosensor-based framework to measure latent proteostasis capacity, Nat Commun 9, 287. [0204] [23] Kitamura, A., Nagata, K., and Kinjo, M. (2015) Conformational Analysis of Misfolded Protein Aggregation by FRET and Live-Cell Imaging Techniques, Int JMol Sci 16, 6076-6092. [0205] [24] Walker, C. L., Lukyanov, K. A., Yampolsky, I. V., Mishin, A. S., Bommarius, A. S., Duraj-Thatte, A. M., Azizi, B., Tolbert, L. M., and Solntsev, K. M. (2015) Fluorescence imaging using synthetic GFP chromophores, Curr Opin Chem Biol 27, 64-74. [0206] [25] Tsien, R. Y. (1998) The green fluorescent protein, Annual Review of Biochemistry 67, 509-544. [0207] [26] Zimmer, M. (2002) Green fluorescent protein (GFP): applications, structure, and related photophysical behavior, Chem Rev 102, 759-781. [0208] [27] Subach, F. V., and Verkhusha, V. V. (2012) Chromophore transformations in red fluorescent proteins, Chem Rev 112, 4308-4327. [0209] [28] Baranov, M. S., Lukyanov, K. A., Borissova, A. O., Shamir, J., Kosenkov, D., Slipchenko, L. V., Tolbert, L. M., Yampolsky, I. V., and Solntsev, K. M. (2012) Conformationally locked chromophores as models of excited-state proton transfer in fluorescent proteins, J Am Chem Soc 134, 6025-6032. [0210] [29] Baldridge, A., Samanta, S. R., Jayaraj, N., Ramamurthy, V., and Tolbert, L. [0211] M. (2011) Steric and electronic effects in capsule-confined green fluorescent protein chromophores, J Am Chem Soc 133, 712-715. [0212] [30] Williams, D. E., Dolgopolova, E. A., Pellechia, P. J., Palukoshka, A., Wilson, T. J., Tan, R., Maier, J. M., Greytak, A. B., Smith, M. D., Krause, J. A., and Shustova, N. B. (2015) Mimic of the green fluorescent protein beta-barrel: photophysics and dynamics of confined chromophores defined by a rigid porous scaffold, J Am Chem Soc 137, 2223-2226. [0213] [31] Carayon, C., Ghodbane, A., Gibot, L., Dumur, R., Wang, J., Saffon, N., Rols, [0214] M. P., Solntsev, K. M., and Fey-Forgues, S. (2016) Conjugates of Benzoxazole and GFP Chromophore with Aggregation-Induced Enhanced Emission: Influence of the Chain Length on the Formation of Particles and on the Dye Uptake by Living Cells, Small 12, 6602-6612. [0215] [32] Baldridge, A., Feng, S., Chang, Y. T., and Tolbert, L. M. (2011) Recapture of GFP chromophore fluorescence in a protein host, ACS Comb Sci 13, 214-217. [0216] [33] Paige, J. S., Wu, K. Y., and Jaffrey, S. R. (2011) RNA mimics of green fluorescent protein, Science 333, 642-646. [0217] [34] Filonov, G. S., Moon, J. D., Svensen, N., and Jaffrey, S. R. (2014) Broccoli: rapid selection of an RNA mimic of green fluorescent protein by fluorescence-based selection and directed evolution, J Am Chem Soc 136, 16299-16308. [0218] [35] Warner, K. D., Sjekloca, L., Song, W., Filonov, G. S., Jaffrey, S. R., and Ferre-D′Amare, A. R. (2017) A homodimer interface without base pairs in an RNA mimic of red fluorescent protein, Nat Chem Biol 13, 1195-1201. [0219] [36] Feng, G., Luo, C., Yi, H., Yuan, L., Lin, B., Luo, X., Hu, X., Wang, H., Lei, C., Nie, Z., and Yao, S. (2017) DNA mimics of red fluorescent proteins (RFP) based on G-quadruplex-confined synthetic RFP chromophores, Nucleic Acids Res 45, 10380-10392. [0220] [37] Kellenberger, C. A., Wilson, S. C., Sales-Lee, J., and Hammond, M. C. (2013) RNA-based fluorescent biosensors for live cell imaging of second messengers cyclic di-GMP and cyclic AMP-GMP, JAm Chem Soc 135, 4906-4909. [0221] [38] Tsien, R. Y., and Miyawaki, A. (1998) Seeing the machinery of live cells, Science 280, 1954-1955. [0222] [39] Rodriguez, E. A., Campbell, R. E., Lin, J. Y., Lin, M. Z., Miyawaki, A., [0223] Palmer, A. E., Shu, X., Zhang, J., and Tsien, R. Y. (2017) The Growing and Glowing Toolbox of Fluorescent and Photoactive Proteins, Trends Biochem Sci 42, 111-129. [0224] [40] Ando, R., Hama, H., Yamamoto-Hino, M., Mizuno, H., and Miyawaki, A. (2002) An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein, Proc Nat Acad Sci USA 99, 12651-12656. [0225] [41] Tomura, M., Yoshida, N., Tanaka, J., Karasawa, S., Miwa, Y., Miyawaki, A., and Kanagawa, O. (2008) Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice, Proc Natl Acad Sci USA 105, 10871-10876. [0226] [42] Lashuel, H. A., Overk, C. R., Oueslati, A., and Masliah, E. (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target, Nat Rev Neurosci 14, 38-48. [0227] [43] Qin, L., Vastl, J., and Gao, J. (2010) Highly sensitive amyloid detection enabled by thioflavin T dimers, Molecular BioSystems 6, 1791-1795. [0228] [44] Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, [0229] A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H. X., and et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature 362, 59-62. [0230] [45] Dangoumau, A., Verschueren, A., Hammouche, E., Papon, M. A., Blasco, H., Cherpi-Antar, C., Pouget, J., Corcia, P., Andres, C. R., and Vourc'h, P. (2014) Novel SOD1 mutation p.V31A identified with a slowly progressive form of amyotrophic lateral sclerosis, Neurobiol Aging 35, 266 e261-264. [0231] [46] Kaganovich, D., Kopito, R., and Frydman, J. (2008) Misfolded proteins partition between two distinct quality control compartments, Nature 454, 1088-U1036. [0232] [47] Sontag, E. M., Vonk, W. I. M., and Frydman, J. (2014) Sorting out the trash: the spatial nature of eukaryotic protein quality control, Curr Opin Cell Biol 26, 139-146. [0233] [48] Long, M. J. C., Poganik, J. R., and Aye, Y. (2016) On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry, J Am Chem Soc 138, 3610-3622. [0234] [49] Lin, H. Y., Haegele, J. A., Disare, M. T., Lin, Q. S., and Aye, Y. (2015) A Generalizable Platform for Interrogating Target- and Signal-Specific Consequences of Electrophilic Modifications in Redox-Dependent Cell Signaling, J Am Chem Soc 137, 6232-6244. [0235] [50] Keppler, A., Gendreizig, S., Gronemeyer, T., Pick, H., Vogel, H., and Johnsson, K. (2003) A general method for the covalent labeling of fusion proteins with small molecules in vivo, Nat Biotechnol 21, 86-89. [0236] [51] Gautier, A., Juillerat, A., Heinis, C., Correa, I. R., Jr., Kindermann, M., Beaufils, F., and Johnsson, K. (2008) An engineered protein tag for multiprotein labeling in living cells, Chemistry & Biology 15, 128-136. [0237] [52] Xue, L., Karpenko, I. A., Hiblot, J., and Johnsson, K. (2015) Imaging and manipulating proteins in live cells through covalent labeling, Nat Chem Biol 11, 917-923. [0238] [53] Jung, K. H., Fares, M., Grainger, L. S., Wolstenholme, C. H., Hou, A., Liu, Y., and Zhang, X. (2018) A SNAP-tag fluorogenic probe mimicking the chromophore of the red fluorescent protein Kaede, Org Biomol Chem. [0239] [54] Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., and Puschmann, H. (2009) OLEX2: a complete structure solution, refinement and analysis program, J Appl Crystallogr 42, 339-341. [0240] [55] Sheldrick, G. M. (2008) A short history of SHELX, Acta Crystallogr A 64, 112-122.